Angiotensin-(1-7) and its receptor as a potential targets for new cardiovascular drugs

Santos, R.A.,, Ferreira, A.J., Pinheiro, S.V.B., Sampaio, W.O., Touyz, R.M. and Campagnole-Santos, M.J. (2005) Angiotensin-(1-7) and its receptor as a potential targets for new cardiovascular drugs. Expert Opinion on Investigational Drugs, 14(8), pp. 1019-1031. (doi: 10.1517/13543784.14.8.1019)

Full text not currently available from Enlighten.

Abstract

he identification of novel biochemical components of the renin–angiotensin system (RAS) has added a further layer of complexity to the classical concept of this cardiovascular regulatory system. It is now clear that there is a counter-regulatory arm within the RAS that is mainly formed by the angiotensin-converting enzyme 2–angiotensin (1-7)–receptor Mas axis. The functions of this axis are often opposite to those attributed to the major component of the RAS, angiotensin II. This review will highlight the current knowledge concerning the cardiovascular effects of angiotensin-(1-7) through a direct interaction with its receptor Mas or through an indirect interplay with the kallikrein–kinin system. In addition, there will be a discussion of its role in the beneficial effects of angiotensin-converting enzyme inhibitors and angio-tensin receptor type 1 (AT<sub>1</sub>) antagonists, and the potential of this peptide and its receptor as a novel targets for new cardiovascular drugs.

Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Touyz, Professor Rhian
Authors: Santos, R.A.,, Ferreira, A.J., Pinheiro, S.V.B., Sampaio, W.O., Touyz, R.M., and Campagnole-Santos, M.J.
College/School:College of Medical Veterinary and Life Sciences > Institute of Cardiovascular and Medical Sciences
Journal Name:Expert Opinion on Investigational Drugs
ISSN:1354-3784
ISSN (Online):1744-7658

University Staff: Request a correction | Enlighten Editors: Update this record